Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Novel combination shows survival benefits in high-risk gastric/gastro-oesophageal junction cancer
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Zanzalintinib plus atezolizumab shows activity in metastatic colorectal cancer with microsatellite stable disease
Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases
ctDNA shapes anti-EGFR rechallenge strategies in metastatic colorectal cancer
Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge
How can regular exercise be integrated into the patient journey?
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
The long road toward treatment personalisation for pancreatic and rectal cancers
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
ctDNA testing may help refine surveillance strategy for colorectal cancer
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed